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Recent discoveries indicate that transcriptional
elongation is an important regulatory step in gene
expression, and that deregulation of elongation can
lead to the development of certain malignancies.
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It is well established that deregulation of transcription can
cause cancer, and the protein products of many oncogenes,
proto-oncogenes and tumor suppressor genes are transcrip-
tion factors. It has been assumed that the deregulation
would occur at the level of initiation, the first step in trans-
cription and the one that has commanded most attention.
However, two recent findings call that assumption into
question by showing that the deregulation can also occur at
the level of transcriptional elongation.
The von Hippel-Lindau syndrome is a hereditary disor-
der that predisposes affected individuals to multiple
forms of cancer. The disease is caused by the lack of
expression, or mutation, of the VHL gene, the product of
which is therefore a tumor suppressor [1]. To gain insight
into the function of the VHL gene product, several groups
have analyzed the proteins with which pVHL interacts
[2,3]. Two polypeptides were identified that associate
with a region of pVHL that is frequently mutated in
tumors of patients with von Hippel-Lindau syndrome.
Unexpectedly, these polypeptides correspond to the B
and C subunits of a well characterized transcriptional
elongation factor, Elongin (SIII).
Elongin (SIII) is comprised of three subunits [4]. Whereas
Elongin A can, by itself, stimulate elongation, its activity
is enhanced by the other two subunits, Elongin B and C.
These observations, and other in vitro results [2,3], suggest
that pVHL normally binds to, and sequesters, Elongin B
and C, thereby downregulating Elongin (SIII)-mediated
transcriptional elongation. In afflicted individuals, the
mutation (or absence) of pVHL prevents binding to
Elongin B and C and therefore transcriptional elongation
is inappropriately upregulated (Fig. 1).
A further indication that pVHL plays a central role in
growth control is that its cellular localization changes in
response to cell density: pVHL is nuclear in sparsely cul-
tured cells and cytoplasmic in densely cultured cells [5].
However, this localization pattern is opposite to that
expected if pVHL is acting to suppress cellular prolifera-
tion. This curiosity remains to be explained. 
The second connection between cancer and transcrip-
tional elongation comes from studies of the ELL (also
called MEN ) gene, first identified in a chromosomal
translocation, t(11;19)(q23;p13.1), implicated in certain
acute myeloid leukemias [6]. Whereas the sequence of the
ELL protein did not reveal its function, a recent study [7]
found that it is a biochemically defined elongation factor.
Two proteins have thus recently been implicated in
cancer, of which one, pVHL, regulates transcriptional
elongation, whereas the other, ELL, is itself a transcrip-
tional elongation factor.
These new findings strongly reinforce the notion that gene
expression can be controlled at the level of transcriptional
elongation and raise the question: how does deregulation
Figure 1
Regulation of transcription by the von Hippel-
Lindau tumor suppressor gene product pVHL.
The transcription elongation factor Elongin
(SIII) is a complex of subunits A, B, and C:
subunit A contains intrinsic elongation activity,
which is stimulated by interaction with
subunits B and C. In normal cells, wild type
pVHL regulates Elongin (SIII) activity by
sequestering Elongin B and C, preventing
their association with Elongin A. In VHL cells,
Elongin B and C associate with Elongin A in
an unchecked manner, resulting in
unregulated elongation.
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of elongation result in cancer? The answer, presumably, is
by affecting the expression of a particular target gene(s)
whose product is involved in growth control. In fact, some
genes involved in growth control, such as c-myc and c-fos,
have been long known to be controlled, at least in part, at a
post-initiation step [8]. However, this hardly narrows the
field; many genes are presumably regulated at the tran-
scriptional elongation level. For example, immunofluores-
cence studies of Drosophila polytene chromosome have
detected the association of RNA polymerases with many
non-transcribed genes, suggesting that regulation occurs at
a post-initiation step [9].
A recent study suggests that pausing of RNA polymerase
II in the promoter-proximal region occurs under a variety
of conditions, and may be a general rate-limiting step in
transcription [10]. Furthermore, a generic basal promoter,
containing a TATA box or initiator element, is sufficient
to direct formation of a nonprocessive elongation complex.
In fact, in vitro transcription studies suggest that basal
elongation is very inefficient and is subject to ‘road blocks’
such as certain DNA sequences and nucleosomes [8].
Thus, transcriptional pausing may be the ‘default’ state,
which must be overcome by regulator proteins, presum-
ably promoter-specific transcriptional activators.
Most studies on activators have focused exclusively on their
ability to stimulate transcriptional initiation. Recent studies,
however, have shown that activators can also regulate tran-
scriptional elongation. Importantly, there are significant dif-
ferences amongst activators in their ability to stimulate
elongation [10,11]. The processivity of an elongation
complex may therefore depend upon the composition of
activators at the promoter. This may help explain why a
general alteration in the elongation machinery can have
apparent gene-specific effects.
The molecular mechanisms by which promoter-bound
activators regulate transcriptional elongation is poorly
understood. Some studies have shown that paused and
active elongation complexes differ from one another in
the phosphorylation status of the carboxy-terminal
domain (CTD) of RNA polymerase II [9,12]. Thus, acti-
vators may stimulate transcriptional elongation by pro-
moting phosphorylation of the RNA polymerase II CTD.
Alternatively, activators may recruit an ‘elongation stimu-
latory factor’ to the elongation complex; this is believed to
be the mechanism by which the human immunodefi-
ciency virus type 1 (HIV-1) transactivator Tat protein
functions [13].
Transcriptional elongation is thus emerging as an impor-
tant regulatory step in gene expression and cell growth
control. While regulation of elongation is currently poorly
understood, the recent findings provide an additional
incentive and new reagents to attack this problem.
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